parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in microglia (7582 nCPM)	1.00
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 75	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 16522

PLXDC2 in microglia, braak+0.03 (p 0.946) → +0.29 (p 0.456)receipt 16529
PLXDC2 in dopamine neurons, braak+0.47 (p 0.197) → -0.07 (p 0.857)receipt 16530

receipt 16530: PLXDC2 in dopamine neurons, braak

power: full sample +0.21 (p 0.393, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.21 (p 0.393, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.20 (p 0.424, n 18). could be the mix.
skeptic: leave-one-out range +0.14 to +0.40, sign flips 0; without severely affected donors +0.21 (p 0.393, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PLXDC2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 16529: PLXDC2 in microglia, braak

power: full sample +0.15 (p 0.544, n 18), 95% CI -0.34 to +0.58. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.16 (p 0.526, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.22 (p 0.389, n 18). could be the mix.
skeptic: leave-one-out range +0.05 to +0.32, sign flips 0; without severely affected donors +0.15 (p 0.544, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PLXDC2 in microglia.

case closed: nothing better to follow up.

loading the receipts